Tuesday, June 18, 2019
News
NEWS HOME
»
PRN INDIA
A New Approach to Treating Alzheimer's Disease Receives Major NIA Backing
  SocialTwist Tell-a-Friend  
   

T3D Therapeutics to Receive $9 Million Multiyear National Institute on Aging Grant for Phase 2 PIONEER Study in Mild-to-Moderate Alzheimer's Disease Patients

RESEARCH TRIANGLE PARK, North Carolina, May 20, 2019 /PRNewswire/ --  T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the "Company"), a new orally administered treatment for Alzheimer's disease (AD), announced today that it has received a grant expected to total $9 million dollars over four years from the National Institute on Aging (NIA), part of NIH, to help fund a Phase 2 clinical study of T3D-959, a novel, metabolic-focused AD drug treatment.

The Phase 2 PIONEER study (Prospective therapy to Inhibit and Overcome Alzheimer's Disease Neurodegeneration via Brain EnErgetics and Metabolism Restoration) is expected to initiate patient dosing in early 2020. PIONEER is a  double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study expected to enroll up to 252 adults with mild-to-moderate Alzheimer's disease (MMSE 16-26). PIONEER will enroll subjects who will receive one of three different doses of T3D-959 or a placebo for 24 weeks.

"We see this grant award as recognition that improving inherent metabolic defects in Alzheimer's disease is a vital and largely unexplored therapeutic avenue in need of pursuit is a testament to the potential for T3D-959 to treat AD, a disease that we view as a chronic anorexia of the brain" said Chief Executive Officer  John Didsbury, Ph.D.  "We are truly honored by the support of the NIA and the confidence that our peers have shown in the science underpinning T3D-959."

"Given the enormous and growing impact of Alzheimer's on patients and families, there is an urgent need to develop and rigorously evaluate a larger and more diversified portfolio of promising late clinical stage treatments," said George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer's. "NIA's support of Phase 2 studies - including this study from  T3D Therapeutics - is to be commended and scaled if we are going to achieve our national goal of effectively treating Alzheimer's in the near future."

"NIA/NIH and its peer review system are to be lauded for supporting the logic of this new approach and excellent science of the T3D-959 program" said Robert Ingram, former Chief Executive Officer and Chairman of Glaxo/Wellcome.

Warren Strittmatter, M.D., Chief Medical Officer of T3D Therapeutics,  Emeritus Professor of Neurology at Duke University Medical Center and Alzheimer's Association Zenith Award winner said, "During my lengthy tenure treating AD patients I have seen firsthand the frustrations of caregivers and patients at the lack of an effective therapy with the plethora of recent drug development failures causing them to lose hope.  This award  provides great support for our promising new therapy to give them renewed optimism.  AD is being increasingly  recognized as  resulting from  abnormal brain metabolism.  T3D-959 is targeted toward  those metabolic pathways which appear  to  ultimately  produce amyloid plaques, tau tangles, inflammation and, most importantly, the  dementia."  

PIONEER is supported by the NIA under award number R01AG061122.

About T3D Therapeutics, Inc.

T3D Therapeutics, Inc. is a privately-held, Research Triangle Park, NC-based company. The Company has an exclusive license to T3D-959, its lead product candidate, and a platform of structurally-related molecules. T3D Therapeutics' mission is to develop and commercialize T3D-959 for the treatment of Alzheimer's disease and Mild Cognitive Impairment. T3D-959 is a small molecule, orally-delivered, brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders.

For more information visit http://www.t3dtherapeutics.com/.

Investor Contact

John Didsbury, Ph.D., CEO
T3D Therapeutics, Inc.
1-919-237-4897
Email: info (at) t3dtherapeutics (dot) com

More News by PR Newswire India

Artprice (New York) - Thierry Ehrmann: Patrick Drahi's Acquisition of Sotheby's Confirms the Art Market's Entry Into the Digital Era of the 21st Century

Citi, Societe Generale, DNB and other leading international banks promote greener global shipping through new principles

Bitdefender Expands APAC Presence With New Strategic Hire

IGP (Israel Growth Partners) Together With Its Major LPs Invest $110M in Cellebrite

The HONOR 20 Color Report: 'Positivity' in Vogue in Fashion Capitals London and Milan

LONGi ranked the most financially stable PV manufacturer by Bloomberg NEF

GCL System Integration Among First Companies Awarded LeTID test Certificate from TÃœV Rheinland

Canopy Growth provides update on international operations and activities

Polygoons, Inc Enhances its Augmented and Virtual Reality Technology

Coursmy Launches Global Live and Video E-learning Marketplace Platform

6th Anniversary of BTC Futures Trading, OKEx Enhanced Risk Management System for a Better "Future"

DLF CYBERHUB and AMPM Café Celebrated Father's Day With Harley-Davidson Riders

Thailand's surge in IMD competitiveness list reflects dynamic economy, says BOI

TB Joshua to Host Meeting in Nazareth, Israel

OPPO Roars for Team India; Released Song ‘Jeet Pe Apna Haq Hai’ Created With Fans’ Heartbeats

From Black Hole Imaging to NASA Climate Research - Supermicro High-Performance Systems Support Major Scientific Discovery & Exploration Even to Distant Galaxies

Seamless Air Alliance showcases technologies enabling the future of inflight connectivity at Paris Air Show 2019

Sino-Russian (Harbin) economic and trade index launched to serve as barometer of bilateral trade

Danone and Migros CEOs Elected New Co-Chairs of The Consumer Goods Forum Board

Anant National University Welcomes its New Provost, Dr Anunaya Chaubey

One Man's Dream - India's Digital Awakening

Snehal Nagarsheth Joins Anant National University as Dean, School of Architecture

Systech and Toppan Sign Partnership Agreement to Deliver Brand Protection Solutions Worldwide

Top 10 Disruptive Digital Media Houses to Watch Out for in 2019-20

The 2019 China and South Asia Aviation Trends Forum Promotes Common Development through Interconnection and Cooperation

edelkrone Introduces Their First ORTAK Product

Health Horizons' Original Recipes Transform the Hemp Industry

FE CREDIT, Focussed on First Time Card Users in Vietnam, Crosses the One Million Cards Milestone and Gets the "Best in Card Acquisition" Award from Mastercard.

SALT Announces Its Signature Global Thought Leadership Conference In Abu Dhabi, UAE

The Cost of Anti-Money Laundering Compliance in Asia Pacific Region Increased 10% in Past 24 Months, Finds Study by LexisNexis Risk Solutions

Kemin Launches New Vision and Logo for the Future

Rove At The Park Opens Doors to a Thrilling Lifestyle Experience in Dubai Parks and Resorts

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Hyderabad police bust cricket betting ra...
BJP, casino lobby trying to oust Goa Con...
Rahul forgets to sign Parliament registe...
Lok Sabha members take oath in different...
Low-profile Nadda rose from ABVP ranks (...
Days after Pakistan alert, 9 soldiers in...
More...    
 
 Top Stories
6 killed, 75 injured in China earth... 
Egypt's ousted President dies durin... 
Circular economy can generate 1.4 c... 
India will overtake China as world'... 
Goa's three M's are priority of gov... 
UP: 6 dead, several injured in Sita... 
Six ministers of Kamal Nath cabinet... 
New police commissioner for Bengalu...